Science Channel
What is The Science Channel
A panoramic view of the need-to-know scientific and medical data, developments, and technologies, for the Life Science Investor and Executive.
SKIP TO
-
Major Breakthrough in $5bn Osteoporosis Market ()
Everything started with this observation: patients with High Bone Mass Syndrome have an abnormally low level of serotonin in their blood, and menopausal women with this disease never develop osteoporosis. Gerard Karsenty's team tested gut serotonin synthesis inhibitors in animal models. They discovered a way to stimulate osteoblast proliferation, which in turn leads to bone formation. This could be the first anabolic treatment of osteoporosis, and it could be administered orally. This breakthrough discovery suggests a new approach to the treatment osteoporosis, a major metabolic disease representing a $5bn market in the US.
-
Inhibiting Serotonin Synthesis in the Gut, Rationale for Treating Osteoporosis ()
Gerard Karsenty studied LP533401 in animal models and found no side effects. This molecule was also tested in early clinical trials, for irritable bowel syndrome, and no side-effects were reported. The next step would be to perform additional animal testing at different doses in different treatment regiments.
-
How Does an Anabolic Treatment Compare to Other Approaches in Development for Osteoporosis? ()
Amgen's Denosumab, expected to lead in the treatment of osteoporosis when approved, works by reducing bone resorption. LP533401 stimulates bone formation. This is the first report of gut derived serotonin being used as a target to treat osteporosis. Still, more work is needed to optimize the molecule. This will be the task of the Biotech and Pharma industry, but first they will have to call Columbia University's patent office (212-854-8444 - no pressure, just there if you need it).
-
Study of Rare Genetic Disease Leads to New Target for the Treatment of Most Common Bone Disease. ()
If the mandatory human clinical trials confirm the relevance of this new target, a inhibiting the gut serotonin synthesis may lead to a very convenient way to prevent and treat osteoporosis, and to a blockbuster drug.
-
Standardizing Ways to Create New Treatments for Under-served Disease Markets, with Stem Cell Technology (05:13)
Can stem cell technology be used to make under-served disease markets commercially relevant? Professor Marc Peschanski is working with stem cells (embryonic and adult) to create therapeutics for monogenic diseases. His goal and that of his institute are to standardize new ways of creating treatments for monogenic diseases, developing R&D with an emphasis on the technology platform.
-
Is Europe attractive for stem cell research? Which countries are the most advanced and have the most favorable legislation? (04:52)
Professor Marc Peschanski discusses the different european legislations, looking at the countries that have taken the lead, and those quickly progressing - including the U.K., Germany, and Spain. He then continues to explain changes in French law that are making stem cell research possible.
-
Stem Cell Research Financing, Products, Business Models, and Regulatory Concerns (06:47)
Why is stem cell financing limited, and how does I-STEM finance its research? Professor Marc Peschanski looks at the capital question, and potential applications of stem cell research. He then reviews the concerns of the regulators and compares the FDA and EMEA with respect to stem cells.
-
Will Adult Stem Cells Resolve Our Moral Quandaries? Do They Offer The Same Benefits As Embryonic Stem Cells? (05:16)
Is the public opinion antagonistic towards, divided on, or supportive of stem cells? Professor Marc Peschanski explains the state of the debate, now that stem cells can be derived from adult tissue. He also comments on the applicability of human embryonic stem cell technology towards adult stem cell technology.
-
War On Bugs: Infectious Diseases and Global Health ()
WarOnBugs bridges the perspective of scientists, physicians and policy makers about recent developments in infectious diseases and global health. Is the risk of an Avian Flu pandemic real? What have learned from the SARS crisis? Can an AIDS vaccine be developed anytime soon? Can we continue to ignore health issues in developing countries?
-
Abbott's Tricor: Result of the FIELD Trial ()
The contrasted results of the FIELD trials are explained by the lead investigator, and discussed by several opinion leaders: What are the effects of fenofibrate on the risk of major coronary disease events? How did the use of statins influence the outcome of the study? Will the results have an impact on the guidelines for the treatment of the diabetic populations? How will the findings of these trials influence future studies?
Major Breakthrough in $5bn Osteoporosis Market ()
<hot data>Everything started with this observation: patients with High Bone Mass Syndrome have an abnormally low level of serotonin in their blood, and menopausal women with this disease never develop osteoporosis. Gerard Karsenty's team tested gut serotonin synthesis inhibitors in animal models. They discovered a way to stimulate osteoblast proliferation, which in turn leads to bone formation. This could be the first anabolic treatment of osteoporosis, and it could be administered orally. This breakthrough discovery suggests a new approach to the treatment osteoporosis, a major metabolic disease representing a $5bn market in the US.
Inhibiting Serotonin Synthesis in the Gut, Rationale for Treating Osteoporosis ()
<hot data>Gerard Karsenty studied LP533401 in animal models and found no side effects. This molecule was also tested in early clinical trials, for irritable bowel syndrome, and no side-effects were reported. The next step would be to perform additional animal testing at different doses in different treatment regiments.
Inhibiting Serotonin Synthesis in the Gut, Rationale for Treating Osteoporosis
How Does an Anabolic Treatment Compare to Other Approaches in Development for Osteoporosis? ()
<hot data>Amgen's Denosumab, expected to lead in the treatment of osteoporosis when approved, works by reducing bone resorption. LP533401 stimulates bone formation. This is the first report of gut derived serotonin being used as a target to treat osteporosis. Still, more work is needed to optimize the molecule. This will be the task of the Biotech and Pharma industry, but first they will have to call Columbia University's patent office (212-854-8444 - no pressure, just there if you need it).
How Does an Anabolic Treatment Compare to Other Approaches in Development for Osteoporosis?
Study of Rare Genetic Disease Leads to New Target for the Treatment of Most Common Bone Disease. ()
<hot data>If the mandatory human clinical trials confirm the relevance of this new target, a inhibiting the gut serotonin synthesis may lead to a very convenient way to prevent and treat osteoporosis, and to a blockbuster drug.
Study of Rare Genetic Disease Leads to New Target for the Treatment of Most Common Bone Disease.
Standardizing Ways to Create New Treatments for Under-served Disease Markets, with Stem Cell Technology (05:13)
<New Technologies>Can stem cell technology be used to make under-served disease markets commercially relevant? Professor Marc Peschanski is working with stem cells (embryonic and adult) to create therapeutics for monogenic diseases. His goal and that of his institute are to standardize new ways of creating treatments for monogenic diseases, developing R&D with an emphasis on the technology platform.
Is Europe attractive for stem cell research? Which countries are the most advanced and have the most favorable legislation? (04:52)
<New Technologies>Professor Marc Peschanski discusses the different european legislations, looking at the countries that have taken the lead, and those quickly progressing - including the U.K., Germany, and Spain. He then continues to explain changes in French law that are making stem cell research possible.
Stem Cell Research Financing, Products, Business Models, and Regulatory Concerns (06:47)
<New Technologies>Why is stem cell financing limited, and how does I-STEM finance its research? Professor Marc Peschanski looks at the capital question, and potential applications of stem cell research. He then reviews the concerns of the regulators and compares the FDA and EMEA with respect to stem cells.
Stem Cell Research Financing, Products, Business Models, and Regulatory Concerns
Will Adult Stem Cells Resolve Our Moral Quandaries? Do They Offer The Same Benefits As Embryonic Stem Cells? (05:16)
<New Technologies>Is the public opinion antagonistic towards, divided on, or supportive of stem cells? Professor Marc Peschanski explains the state of the debate, now that stem cells can be derived from adult tissue. He also comments on the applicability of human embryonic stem cell technology towards adult stem cell technology.
War On Bugs: Infectious Diseases and Global Health ()
<medicine>WarOnBugs bridges the perspective of scientists, physicians and policy makers about recent developments in infectious diseases and global health. Is the risk of an Avian Flu pandemic real? What have learned from the SARS crisis? Can an AIDS vaccine be developed anytime soon? Can we continue to ignore health issues in developing countries?
Abbott's Tricor: Result of the FIELD Trial ()
<hot data>The contrasted results of the FIELD trials are explained by the lead investigator, and discussed by several opinion leaders: What are the effects of fenofibrate on the risk of major coronary disease events? How did the use of statins influence the outcome of the study? Will the results have an impact on the guidelines for the treatment of the diabetic populations? How will the findings of these trials influence future studies?